Human-derived bacteria that induce proliferation or accumulation of regulatory t cells

Patent metadata

Field	Value
Publication number	US-2019314426-A1
Application number	US-201916427899-A
Country	US
Kind code	A1
Filing date	May 31, 2019
Priority date	Dec 1, 2011
Publication date	Oct 17, 2019
Grant date	—

Abstract

Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.

First claim

What is claimed is:

1 . A method of treating autoimmune disease in a subject, the method comprising administering a pharmaceutical composition comprising a purified bacterial mixture consisting of bacteria comprising 16S rDNA sequences of at least 95% homology to SEQ ID NO: 19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:39; SEQ ID NO:40, SEQ ID NO:41, and SEQ ID NO:42 to the subject in an amount sufficient to treat autoimmune disease.

2 . The method of claim 1 , wherein the autoimmune disease is organ transplant rejection, inflammatory bowel disease (IBD), ulcerative colitis, pouchitis, Crohn's disease, sprue, rheumatoid arthritis, Type 1 diabetes, graft versus host disease, or multiple sclerosis.

3 . The method of claim 2 , wherein the autoimmune disease is inflammatory bowel disease (IBD), ulcerative colitis, pouchitis, or Crohn's disease.

4 . The method of claim 1 , wherein the bacteria are human-derived bacteria.

5 . The method of claim 1 , wherein the bacteria are isolated from a chloroform-treated fecal sample.

6 . The method of claim 1 , wherein the bacteria are isolated from a heat-treated fecal sample.

7 . The method of claim 1 , wherein at least a portion of the bacteria are in spore-form.

8 . The method of claim 1 , further comprising a pharmaceutically acceptable excipient.

9 . The method of claim 1 , wherein the pharmaceutical composition is formulated for oral administration.

10 . The method of claim 1 , wherein the pharmaceutical composition comprises one or more enteric polymers.

Assignees

• Univ Tokyo
• School Corporation Azabu Veterinary Medicine Educational Inst

Inventors

• Honda Kenya
• Atarashi Koji
• Tanoue Takeshi
• Hattori Masahira
• Morita Hidetoshi

Classifications

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61P33/00

  Antiparasitic agents · CPC title